Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Remedent signs distribution agreement in Netherlands
Remedent has agreed to deliver the product in packed form and ready for sale, while the distributor will be responsible to promote and advertise the product to the
Remedent has agreed to deliver the product in packed form and ready for sale, while the distributor will be responsible to promote and advertise the product to the
Results of the studies could provide the basis for developing a blood test that would enable early detection of breast cancer. According to A&G, the award was one
PAC Perfect, a comprehensive skin health system using RadianceGuard-64, was launched into a test-marketing phase on November 20, 2007. Initial response has been strong with over 80% of
According to Oragenics, IVIAT is a unique discovery platform designed to identify genes of pathogenic bacteria that are specifically present when humans have infections. Robert Zahradnik, president and
The study is designed to evaluate the safety and efficacy of ACP-104 in patients with schizophrenia who are experiencing an acute psychotic episode. A total of 248 patients
Under the terms of the collaboration, Alba will receive an initial, non- refundable licensing payment of $25 million. Joint development costs toward global approval of AT-1001 will be
This was the eighth of several regularly scheduled reviews by the Data Safety Monitoring Board (DSMB), including the planned in-depth interim safety analysis, held in April 2007, on
The lawsuit asserts that Watson’s Quasense product infringes Duramed’s US patent number 5,895,032. Watson launched its Quasense product in September 2006 following the FDA’s final approval of its
Wayne Danter, president and chief scientific officer of Critical Outcome Technologies (COTI), said: “Over the last 12 months COTI has made considerable progress in advancing our product pipeline
Whether the complete response and this supplemental submission resolve to the FDA’s satisfaction the issues raised in the approvable letter is not yet known, said Wyeth. The current